ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Catalyst sparks price row in US with $300,000 rare disease drug
February 13, 2019The controversy over rising drug prices in the US has been reignited after it emerged that the yearly cost of the life-sustaining rare disease drug Firdapse has been hiked from free to more than $300,000. -
Tricida files for $150M IPO to fund kidney disease drug approval
June 11, 2018Tricida has filed to raise $150 million to bring a chronic kidney disease drug to market. Proceeds from the planned IPO will set Tricida up to file for FDA approval of TRC101 and start building up the 80- to 100-person sales team it wants to commercialize -
NICE rejects rare eye disease drug
March 22, 2018Cost regulators for NHS therapies in England and Wales have published draft guidelines rejecting funding for Dompé’s cenegermin as a treatment for neurotrophic keratitis, a rare eye condition.
Pharma Sources Insight January 2025
